Biogen Inc.

As of June 30, 2026, Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh carries a market capitalization of 31.05B, placing it among publicly traded companies globally. Its enterprise value stands at 38.12B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh's next confirmed earnings release is scheduled for October 28, 2026.

As of June 30, 2026, Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh has 1.79B shares outstanding.

As of June 30, 2026, Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh trades at a trailing price-to-earnings ratio of 37.04. The price-to-sales ratio is 3.08, and the price-to-book ratio stands at 1.65.

As of June 30, 2026, Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh trades at an EV/EBITDA multiple of 19.68 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.80 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 34.83 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh trades at an EV/FCF ratio of 13.99, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 38.12B versus a market cap of 31.05B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh maintains a current ratio of 1.87, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 44.33, indicating elevated leverage, while an interest coverage ratio of 6.80 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh posted a return on equity (ROE) of 4.58, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 3.50 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.76, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.16, useful for judging operating efficiency across full business cycles. The company generates approximately 1.33M in revenue per employee across its workforce of 7,526.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.12 indicates how many times Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh recorded 176.80M in income tax expense. That works out to an effective tax rate of 17.48, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.01B, leaving 834.60M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh's stock has gained approximately 83.05% over the past 52 weeks. The 50-day moving average sits at 17.44, while the 200-day moving average is 14.21.

Over the twelve months ended June 30, 2026, Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh generated 10.03B in revenue and converted that into 834.60M in net income, yielding earnings per share of 0.46. EBITDA reached 1.94B, while operating income came in at 1.93B.

As of June 30, 2026, Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh holds 1.29B in cash and equivalents against 8.36B in total debt, resulting in a net debt position of 6.81B. Total book value stands at 18.85B, with working capital of 3.39B providing operational flexibility.

Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh produced 2.88B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -388.80M in capital expenditures, free cash flow totaled 2.49B - equivalent to 1.39 per share.

Over the twelve months ended June 30, 2026, Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh posted a gross margin of 73.99, reflecting its pricing power and cost economics. The operating margin of 19.29 and net profit margin of 8.32 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 8.02, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -3.17, meaning Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh has an Altman Z-Score of 5.71, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.